Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIB-725 in Healthy Adults
NCT06815991Phase 1Recruiting
- Sponsor
- Metro International Biotech
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of MIB-725 (4 cohorts), sponsored by Metro International Biotech. Primary endpoints: Treatment-emergent adverse events at 28 days, Treatment-emergent serious adverse events at 28 days and 4 more. Started Feb 2025; status: recruiting.
02
Drugs
MIB-725
Beyond the preview
Go deeper on NCT06815991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06815991.